Which drugs go off patent in 2027?
Four blockbuster drugs with about $17.7B in 2025 worldwide sales lose US exclusivity in 2027, led by Xtandi (Astellas / Pfizer, $6.0B). Three are small-molecule drugs that go generic and one is a biologic that faces biosimilars.
| Drug | Company | Area | 2025 sales | Date basis | US copies | Medicare price |
|---|---|---|---|---|---|---|
| Xtandi | Astellas / Pfizer | Oncology | ≈$6.0B | Patent-expiry estimate | Approved, waiting to launch | 2027 · −48% |
| Trulicity | Eli Lilly | Cardiometabolic | $4.3B | Company guidance | No US filing found | 2028 · pending |
| Ibrance | Pfizer | Oncology | $4.1B | Patent-expiry estimate | Filed with the FDA | 2027 · −50% |
| Lynparza | AstraZeneca / Merck | Oncology | $3.3B | Company guidance | Filed with the FDA | – |
Two of these dates are fixed by a launch, settlement, court ruling or company guidance; two are estimates from patent expiry and could move. Each drug's page has the sources.
| Company | Drugs | 2025 revenue from them | Share of company |
|---|---|---|---|
| Pfizer | Xtandi and Ibrance | $6.3B | 10% |
| Astellas | Xtandi | ≈$6.0B | 45% |
| Eli Lilly | Trulicity | $4.3B | 6.6% |
| AstraZeneca | Lynparza | $3.3B | 5.6% |
| Merck | Lynparza | $1.4B | 2.2% |
For shared drugs, each company is credited with the revenue it reports, so nothing is counted twice. Share is of the company's total 2025 revenue.
Generic launches usually take most of a drug's US volume within months. Biosimilars usually erode a biologic's sales more gradually, because they are harder to make and switching takes longer. Xtandi, Trulicity and Ibrance were also selected for Medicare price negotiation, which can cut Medicare revenue before or alongside US copies.
US exclusivity can end earlier or later than these dates if a court ruling, settlement or new patent changes the picture. See what happened to sales after past patent cliffs →